Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00764634 · ClinicalTrials.gov registry record · Phase 2
Double Blind, Safety and Immunogenicity Study of Recombinant Botulinum Vaccine A/B
A Phase 2 study, sponsored by DynPort Vaccine Company LLC, A GDIT Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 440
- Enrollment target
NCT00764634: Completed Phase 2 study, sponsored by DynPort Vaccine Company LLC, A GDIT Company.
NCT00764634 is a Phase 2 study that has completed, run by DynPort Vaccine Company LLC, A GDIT Company. The registered enrollment target is 440 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (231% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00764634, a Phase 2 study, has completed, sponsored by DynPort Vaccine Company LLC, A GDIT Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 440 participants
- Enrollment target
Study Summary
This Phase 2 study is a double blind, placebo-controlled, randomized, multicenter investigation of rBV A/B-40 vaccine or placebo in healthy adults, using two different three-dose dosing schedules.
Interventions
- BIOLOGICAL Placebo (USP sterile saline for injection)
- BIOLOGICAL rBV A/B-40 vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 440 participants |
| Start Date | 2008-09 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
What the finished NCT00764634 record still lists
NCT00764634 is an interventional study that assigns participants to a tested intervention. The registered 440 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (231% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo (USP sterile saline for injection) is the first listed.
NCT00764634 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00764634 about?
NCT00764634 is a clinical study titled "Double Blind, Safety and Immunogenicity Study of Recombinant Botulinum Vaccine A/B". This Phase 2 study is a double blind, placebo-controlled, randomized, multicenter investigation of rBV A/B-40 vaccine or placebo in healthy adults, using two different three-dose dosing schedules.
What is the current status of trial NCT00764634?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 440 participants. The study started on 2008-09. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00764634?
The interventions under investigation include: Placebo (USP sterile saline for injection) (BIOLOGICAL), rBV A/B-40 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00764634?
This trial is sponsored by DynPort Vaccine Company LLC, A GDIT Company, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00764634's enrollment target sits among peer trials
440 89th of 2000 higher than 1,912 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05114538 · 440 participants · NA
Improving the Part C Early Intervention Service Delivery System for Children with ASD
- NCT05117619 · 440 participants · NA
The HOME Program for Individuals With Traumatic Brain Injury and Family Members
- NCT05602194 · 440 participants · Phase 3
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
- NCT05624879 · 440 participants · NA
Accelerated Resolution Therapy for Early Maladaptive Grief
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia